Surgalign (NASDAQ:SRGA – Get Rating) and Milestone Scientific (NYSE:MLSS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.
Valuation and Earnings
This table compares Surgalign and Milestone Scientific's revenue, earnings per share (EPS) and valuation.
Get
Surgalign alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Surgalign | $90.50 million | 0.26 | -$84.65 million | ($12.57) | -0.28 |
| Milestone Scientific | $10.31 million | 5.28 | -$6.82 million | ($0.12) | -6.58 |
Milestone Scientific has lower revenue, but higher earnings than Surgalign. Milestone Scientific is trading at a lower price-to-earnings ratio than Surgalign, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Surgalign and Milestone Scientific, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Surgalign | 0 | 0 | 1 | 0 | 3.00 |
| Milestone Scientific | 0 | 0 | 0 | 0 | N/A |
Surgalign currently has a consensus price target of $48.75, suggesting a potential upside of 1,300.86%. Given Surgalign's higher possible upside, equities analysts plainly believe Surgalign is more favorable than Milestone Scientific.
Profitability
This table compares Surgalign and Milestone Scientific's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Surgalign | -70.49% | -234.38% | -47.02% |
| Milestone Scientific | -85.20% | -53.11% | -42.01% |
Risk and Volatility
Surgalign has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Institutional and Insider Ownership
14.9% of Surgalign shares are owned by institutional investors. Comparatively, 7.0% of Milestone Scientific shares are owned by institutional investors. 10.3% of Surgalign shares are owned by company insiders. Comparatively, 25.1% of Milestone Scientific shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
About Surgalign
(Get Rating)
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.
About Milestone Scientific
(Get Rating)
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
Receive News & Ratings for Surgalign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgalign and related companies with MarketBeat.com's FREE daily email newsletter.
Surgalign目前的普遍目標價為48.75美元，這意味著潛在的上行空間為1,300.86%。考慮到Surgalign更有可能的上行空間，股票分析師顯然認為Surgalign比里程碑科學公司更有利。